Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study.
Adult
Aged
Aged, 80 and over
Cell- and Tissue-Based Therapy
/ methods
Disease-Free Survival
Endometrial Neoplasms
/ pathology
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
/ pathology
Prognosis
Retrospective Studies
T-Lymphocytes
/ pathology
Treatment Outcome
Uterine Cervical Neoplasms
/ pathology
Uterine Neoplasms
/ pathology
Uterus
/ pathology
Immune-cell therapy
cervical cancer
dendritic cell vaccine
endometrial cancer
prognostic factors
αβT cell therapy
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
23
05
2020
revised:
08
06
2020
accepted:
09
06
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
11
8
2020
Statut:
ppublish
Résumé
In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy using T lymphocytes activated in vitro with or without dendritic cell vaccination in combination with standard therapies in terms of the survival of patients with advanced or recurrent endometrial and cervical cancers of the uterus. A total of 187 patients with advanced or recurrent uterine cancer were enrolled in this study. The correlation between overall survival and various clinical factors was examined by univariate and multivariate analyses. Univariate analysis revealed that the prognosis was improved in uterine cancer patients who received immune-cell therapy without prior chemotherapy or without distant metastasis. Multivariate analysis demonstrated that the absence of prior chemotherapy for endometrial cancer and liver/lung metastasis of cervical cancer are indications for immune-cell therapy. Survival benefit in uterine cancer patients could be potentially obtained by a combination of immune-cell therapy with other therapies.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy using T lymphocytes activated in vitro with or without dendritic cell vaccination in combination with standard therapies in terms of the survival of patients with advanced or recurrent endometrial and cervical cancers of the uterus.
PATIENTS AND METHODS
METHODS
A total of 187 patients with advanced or recurrent uterine cancer were enrolled in this study. The correlation between overall survival and various clinical factors was examined by univariate and multivariate analyses.
RESULTS
RESULTS
Univariate analysis revealed that the prognosis was improved in uterine cancer patients who received immune-cell therapy without prior chemotherapy or without distant metastasis. Multivariate analysis demonstrated that the absence of prior chemotherapy for endometrial cancer and liver/lung metastasis of cervical cancer are indications for immune-cell therapy.
CONCLUSION
CONCLUSIONS
Survival benefit in uterine cancer patients could be potentially obtained by a combination of immune-cell therapy with other therapies.
Identifiants
pubmed: 32727799
pii: 40/8/4729
doi: 10.21873/anticanres.14474
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4729-4740Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.